TGFB1 and idiopathic pulmonary fibrosis: In murine models of IPF, antagonizing TGF-β action via Tβ-RII (as a ligand decoy), P144, an inhibitor of TGF-β activity, or P17, an anti-TGF-β peptide, resulted in potent anti-fibrotic effects[91-93].